Skip to main content
OpenTrials
Completed

NCT Number: NCT02255266

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

This study is conducted in Europe. The aim of this study is to investigate Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in daily Practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Novo Nordisk Investigational Site

Rome, 00144, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects of age above 18 years as per Victoza® SmPC par.4.2 and 5.1 diagnosed with type 2 diabetes receiving the first prescription of liraglutide in 2011

Exclusion criteria

  • None. Available data from all eligible patients for each center, will be included

Treatment and study plan

liraglutide

Drug

No treatment given.

Primary outcomes

  1. Frequency of patients achieving HbA1c reduction of at least 1%-point

    Time frame: Week 0, week 52

Secondary outcomes

  1. Change in HbA1c (Glycosylated haemoglobin))

    Time frame: Week 0, week 104

  2. Change in body weight

    Time frame: Week 0, week 104

  3. Frequency of patients achieving HbA1c reduction of at least 1%-point

    Time frame: After 4 and 24 months of treatment

  4. Frequency of patients achieving HbA1c target (<=7%)

    Time frame: After 4, 12 and 24 months

  5. Frequency of patients achieving a body weight reduction of at least 3%

    Time frame: After 4, 12 and 24 months

  6. Frequency of patients achieving the composite endpoint consisting in: HbA1c reduction of at least 1%-point and body weight reduction of at least 3%

    Time frame: After 4, 12 and 24 months

  7. Percentage of treatment discontinuation for any reason

    Time frame: At 4, 12 and 24 months

  8. Changes in blood pressure and lipid profile

    Time frame: Week 0, week 104

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Oct 2, 2014
Registry last updated
Apr 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.